Passage Bio Stock Forecast
NASDAQ: PASGHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 9, 10:45 AM ET
PASG analyst consensus
Consensus (3 analysts)
buy
Avg. price target
$15.50+305.76%
- Strong buy 0
- Buy 1
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 3 Wall Street analysts covering Passage Bio (2026-10-09), 1 rate the stock a buy or strong buy, 2 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $15.50, with a high estimate of $23.00 and a low estimate of $8.00. The average target implies upside of 305.8% from the current price of $3.82.
The spread between the highest and lowest targets is 187.5%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for PASG.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 1 | 33% |
| Hold | 2 | 67% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $8.00 | +109.42% |
| Average target | $15.50 | +305.76% |
| High target | $23.00 | +502.09% |